Using directed integration of antibody genes by CRISPR/Cas9 and TALENs, the construction of large libraries in mammalian cells containing a single antibody gene/cell has been achieved. This accomplishment has enabled the construction of libraries containing millions of monoclonal, stable, cell lines displaying IgG-formatted antibodies on their surface, and from which novel, high-affinity binders can be isolated. This technology also allows for the selection of antibodies with improved biophysical properties from libraries of variants.
In this webinar, we will describe the innovative antibody discovery technology developed by IONTAS and demonstrate its potential to save time and effort downstream by addressing antibody developability issues during the initial phase of biotherapeutic discovery.
A live Q&A session will follow the presentations, offering you a chance to pose questions to our expert panelists.
Presenter: John McCafferty, PhD
CEO and Founder
Learn about cutting-edge applications, new resources, and upcoming events.
Subscribe to our e-Newsletter